Natera Appoints Solomon Moshkevich as Chief Executive Officer, Marking New Leadership Chapter for Precision Medicine Growth
Natera, Inc., a global leader in cell-free DNA (cfDNA) testing and precision medicine, has announced a significant leadership transition with the appointment of Solomon Moshkevich as its new Chief Executive Officer (CEO) and a member of the company’s Board of Directors, effective immediately. Moshkevich succeeds Steve Chapman, who is stepping down from the CEO position after leading the company through a period of substantial business expansion, product innovation, and commercial growth.
The leadership transition represents an important milestone for Natera as the company continues to strengthen its position in precision medicine, expand its clinical diagnostics portfolio, and develop innovative testing technologies across multiple healthcare areas. With 15 years of experience at Natera, Moshkevich brings extensive knowledge of the company’s operations, products, commercial strategy, and long-term growth priorities.
As part of the transition, Chapman will continue supporting Natera as a consultant for an extended period. He will also remain an advisor to the company’s Board of Directors, providing strategic guidance and helping maintain continuity as Moshkevich assumes responsibility for leading the organization.
The appointment reflects Natera’s decision to promote an experienced internal leader who has played a central role in the company’s development. Throughout his tenure, Moshkevich has contributed to several major business initiatives, including the development and commercialization of the company’s cell-free DNA testing platforms, expansion into oncology diagnostics, and growth across international markets.
Solomon Moshkevich Brings 15 Years of Leadership Experience at Natera
Moshkevich joined Natera in 2011 and has held several senior leadership positions during his 15-year career with the company. Throughout this period, he has established, developed, and managed multiple teams responsible for supporting Natera’s business operations, clinical development, commercial activities, and product innovation.
His leadership responsibilities have extended across global marketing, product management, medical and scientific affairs, commercial operations, clinical trial operations, international sales, business development, regulatory and quality affairs, and portfolio strategy.
This broad experience has provided Moshkevich with an understanding of the different operational and scientific capabilities required to develop and commercialize advanced diagnostic technologies. His contributions have also positioned him as one of the company’s key executives, with involvement in major strategic and business decisions throughout Natera’s expansion.
One of his most significant contributions has been his leadership in the development, clinical validation, and commercial success of Natera’s cell-free DNA testing portfolio. These technologies have supported the company’s growth across reproductive health, oncology, and organ health, providing healthcare professionals with additional diagnostic information to support clinical decision-making.
Moshkevich has played a leading role in advancing several of Natera’s established products, including Panorama™, Prospera™, and Signatera™.
- Panorama™: Natera’s non-invasive prenatal testing platform, designed to provide genetic screening information during pregnancy and support reproductive healthcare decisions.
- Prospera™: A molecular testing platform focused on organ health, including transplant monitoring and the assessment of potential organ rejection.
- Signatera™: A personalized, tumor-informed molecular residual disease (MRD) testing platform used in cancer management to help detect and monitor cancer-associated circulating tumor DNA.
These platforms represent important components of Natera’s precision medicine strategy and demonstrate the company’s efforts to apply advanced molecular testing technologies across different areas of patient care.
Most recently, Moshkevich served as President of Clinical Diagnostics. In this position, he played an integral role in managing the company’s clinical diagnostics business and advancing its strategic priorities.
He also contributed significantly to Natera’s expansion into oncology, overseeing a period of substantial growth after becoming the company’s first General Manager of Oncology. His experience in developing oncology operations and commercializing cancer-focused diagnostic technologies is expected to remain important as Natera continues expanding its presence in the precision oncology market.
Steve Chapman to Continue Supporting Natera Following CEO Transition
Chapman will step down from his position as Chief Executive Officer but will continue working with the company as a consultant for an extended period. His ongoing advisory role with the Board of Directors is intended to support leadership continuity and provide strategic guidance during the transition.
Reflecting on the appointment, Chapman expressed confidence in Moshkevich’s ability to lead Natera into its next phase of development. He highlighted their long-standing professional relationship, noting that he personally hired Moshkevich in 2011 and has worked closely with him throughout the company’s growth.
Chapman emphasized that Moshkevich has been involved in virtually every major decision made by Natera and has played an important role in shaping the organization’s business strategy and operational development.
He also expressed pride in the company’s achievements during his tenure as CEO, particularly its impact on patient care and its substantial financial growth.
According to Chapman, Natera has made a meaningful difference in the lives of millions of patients through its diagnostic technologies while increasing its revenue approximately tenfold during his leadership. The company has also generated significant value for shareholders through continued innovation, market expansion, and the development of an experienced leadership team.
Chapman attributed these achievements to the collective efforts of Natera’s employees and leadership team, emphasizing that the company has established a strong foundation for continued business growth.
He described the leadership transition as an appropriate step for the organization, expressing confidence that the existing team is well positioned to build on the company’s progress and execute its future strategy.
Chapman also reaffirmed his commitment to supporting Natera following his departure from the CEO position, highlighting the importance of maintaining continuity as the organization enters its next stage of development.
Natera Board Recognizes Chapman’s Contributions and Supports Internal Leadership Succession
Matthew Rabinowitz, PhD, Executive Chairman and Co-Founder of Natera, also recognized Chapman’s contributions to the company’s development and expressed appreciation for his leadership and dedication.
On behalf of the Board of Directors, Rabinowitz highlighted Chapman’s role in expanding presence in women’s health and supporting the company’s entry into oncology and organ health.
During his tenure, introduced several diagnostic products that have influenced clinical practice and expanded the availability of advanced testing options for patients and healthcare providers. Among these, Panorama and were particularly important developments, helping advance the company’s position in reproductive healthcare and cancer diagnostics.
Rabinowitz noted that these products have contributed to improvements in patient care and strengthened reputation as a provider of innovative molecular diagnostic solutions.
He also emphasized that Chapman’s impact extends beyond the company’s commercial achievements, recognizing the importance of diagnostic technologies for patients who depend on its testing services.
In discussing the appointment of Moshkevich, Rabinowitz highlighted the company’s commitment to developing leadership talent internally. He noted that this marks the second time has promoted an established member of its leadership team to the CEO position.
According to Rabinowitz, Moshkevich has spent 15 years helping build the company, initially contributing to its development in reproductive health before taking on increasingly significant responsibilities in organ health and oncology.
His extensive involvement in operations, product portfolio, and commercial strategy provides continuity for the company’s leadership while supporting its long-term objectives.
The Board’s decision to appoint an internal executive also reflects the importance of maintaining the company’s established scientific and commercial direction while pursuing new opportunities in precision medicine.
Moshkevich Outlines Vision for Natera’s Next Phase of Innovation
Following his appointment, Moshkevich expressed appreciation for the opportunity to lead Natera and highlighted the contributions of the company’s employees, leadership team, and previous CEO.
He acknowledged Chapman’s mentorship and leadership, recognizing the important role he played in building business and expanding its impact on patients and healthcare providers.
Moshkevich described as an organization focused on transforming medical practice through advanced diagnostic technologies that enable earlier and more targeted interventions.
The company’s broader objective is to provide healthcare professionals with information that can help identify patients who may benefit from treatment while reducing unnecessary interventions for those who do not require them.
This approach is central to precision medicine, where diagnostic insights are increasingly used to support individualized treatment decisions based on a patient’s specific biological and clinical characteristics.
Under Moshkevich’s leadership, intends to continue investing in diagnostic innovation, expand the applications of its existing technologies, and explore opportunities to bring molecular testing to additional patient populations.
He outlined several priorities for the company’s next phase of development.
Generating more diagnostic insights from clinical samples
One of Natera’s key priorities will be to extract additional clinical information from every sample collected from patients. Advances in molecular diagnostics and analytical technologies could help the company expand the amount of clinically relevant information available to healthcare professionals.
By developing more sophisticated approaches to analyzing cell-free DNA and other molecular biomarkers, aims to support improved disease detection, monitoring, and treatment management.
Expanding technologies into new patient populations
Another priority involves bringing innovative diagnostic technologies to a broader range of patients and clinical applications.
Natera’s established presence in reproductive health, oncology, and organ health provides opportunities to explore additional uses for its molecular testing platforms. Expanding these technologies could help address unmet diagnostic needs across different medical specialties.
Improving integration at the point of care
Moshkevich also highlighted the importance of integrating diagnostic solutions more seamlessly into clinical workflows.
Improved integration at the point of care could make diagnostic information more accessible to healthcare professionals and support timely clinical decisions. Strengthening connections between testing services, laboratory operations, and healthcare providers may also improve the overall patient experience.
Advancing the future of precision medicine
Natera intends to contribute to the next generation of precision medicine through continued research, product development, clinical validation, and commercial expansion.
As molecular diagnostics become increasingly important in disease management, the company aims to develop technologies that provide more detailed insights into disease biology and help healthcare professionals make more informed treatment decisions.
Moshkevich’s experience across major business areas is expected to support these priorities as the company works to strengthen its position in the global diagnostics market.
Natera’s Cell-Free DNA Technology Supports Its Diversified Diagnostics Portfolio
The leadership transition comes as continues developing its presence across several important areas of healthcare.
Cell-free DNA technology remains central to the company’s business model. This approach analyzes small fragments of DNA circulating in biological samples, including blood, to obtain information that may support disease screening, detection, and monitoring.
Natera has applied this technology across different clinical settings, developing products for prenatal screening, cancer monitoring, and transplant-related diagnostics.
In reproductive health, Panorama has helped establish the company’s presence in non-invasive prenatal screening. In oncology, Signatera supports personalized molecular residual disease testing, while Prospera contributes to the company’s organ health portfolio.
The development and commercialization of these platforms have required coordination across scientific research, clinical validation, regulatory affairs, product management, and commercial operations.
Moshkevich’s experience overseeing these functions provides him with a broad understanding of the company’s technology platforms and the markets in which they operate.
As CEO, he will be responsible for guiding overall strategy, managing its leadership organization, and identifying opportunities to strengthen its diagnostic capabilities and commercial performance.
Natera Reports Third Quarter 2026 Financial Results
Alongside the leadership announcement, Natera separately reported its financial results for the third quarter of 2026.
The company published its earnings release through the investor relations section of its corporate website at investor.natera.com.
Management also scheduled a conference call for 4:30 p.m. Eastern Time to discuss the company’s quarterly financial performance and provide additional business updates.
The third-quarter announcement provides investors and other stakeholders with an opportunity to review financial position, operational performance, and progress across its diagnostic businesses.
The leadership transition and quarterly financial update together represent important developments for the company as it enters the next phase of its corporate strategy.
Leadership Continuity to Support Long-Term Growth
Moshkevich’s appointment marks a new chapter for Natera, with the company choosing an experienced internal executive who has been closely involved in its development for more than a decade.
His background in product development, clinical diagnostics, oncology, reproductive health, organ health, international sales, and commercial strategy provides a foundation for leading the company’s diversified business.
At the same time, Chapman’s continued involvement as a consultant and Board advisor is expected to support a smooth transition and preserve institutional knowledge.
With its established portfolio of cell-free DNA technologies and continued focus on precision medicine, Natera aims to expand its diagnostic capabilities, reach additional patient populations, and strengthen the role of molecular testing in clinical decision-making.
Under Moshkevich’s leadership, the company plans to focus on generating greater diagnostic value from clinical samples, expanding its technologies into new applications, improving integration with healthcare providers, and advancing innovative approaches to personalized patient care.
The leadership change therefore represents both continuity and an opportunity for further expansion as works toward its long-term goal of transforming healthcare through advanced molecular diagnostics.
About Natera
Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, San Carlos, California, and Boulder, Colorado.